Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial


Paz-Ares L., Spira A., Raben D., Planchard D., Cho B. C. , Ozguroglu M. , ...Daha Fazla

ANNALS OF ONCOLOGY, cilt.31, ss.798-806, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 31 Konu: 6
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1016/j.annonc.2020.03.287
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Sayfa Sayıları: ss.798-806

Özet

Background: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chemoradiotherapy (CRT). We report exploratory analyses of outcomes by tumour cell (TC) programmed death-ligand 1 (PD-L1) expression.